What is the mRNA Clinical Trial Enabling Infrastructure Grant?
The mRNA Clinical Trial Enabling Infrastructure Grant opportunity is a program that provides organisations with funding to use and enhance emerging technologies, platforms, equipment and infrastructure to conduct clinical trials of mRNA-based vaccines and/or therapeutics.
The 2021 mRNA Clinical Trial Enabling Infrastructure grant is part of the Medical Research Future Fund (MRFF) and the Coronavirus Research response. This opportunity looks to fund an organisation who has applied to the Department of Industry, Science, Energy and Resources (DISER) and Department of Health’s Approach To Market: Enabling Australia’s onshore mRNA manufacturing capability. In addition, they must specify at least one state government partner organisation contributing to the research.
The objective of this grant opportunity is to provide funding to Australian medical research and medical innovation projects that leverage and enhance emerging technologies, platforms, equipment and infrastructure to conduct clinical trials of mRNA-based vaccines and/or therapeutics.
A fixed grant amount of $5 million over 3 years from 2022-23 to develop our onshore mRNA vaccine manufacturing capability.
The program can only accept applications where you can provide:
- details of your nominated Chief Investigator A (CIA) who will take the lead role in conducting the project
- evidence from your board (or chief executive officer or equivalent if there is no board) that the project is supported, and that you can complete the project and meet the costs of the project not covered by grant funding
- letters of support from each project partner
- all mandatory attachments.
To be eligible your project must:
- be aimed at the objectives
- include one or more of the following eligible activities:
- minor capital works
- development/installation of research equipment
- employment of personnel and/or
- other direct research costs.
You can apply if you:
- have an Australian business number (ABN)
- are incorporated in Australia
You must also be one of the following entities:
- a medical research institute
- a university
- a corporate Commonwealth entity
- a corporation (including businesses and not for profits).
In addition you or a partner organisation must have applied to the (DISER) and Department of Health’s Approach To Market: Enabling Australia’s onshore mRNA manufacturing capability program and must have at least one state government partner organisation.
You can’t apply if you are:
- an organisation, or your project partner is an organisation, included on the National Redress Scheme’s list of Institutions that have not joined or signified their intent to join the Scheme– external site
- an employer of 100 or more employees that has not compliedwith the Workplace Gender Equality Act (2012)
- an individual
- unincorporated association
- trust (however, an incorporated trustee may apply on behalf of a trust)
- a non-corporate Commonwealth entity.
Applications close 15 July 2022.